Literature DB >> 26234660

Echocardiographic Guided Closure of Perimembranous Ventricular Septal Defects.

Wen-Bin Ou-Yang1, Shou-Jun Li1, Shou-Zheng Wang1, Da-Wei Zhang1, Yao Liu1, Zhe Zhang1, Yi Ge1, Xiang-Bin Pan2.   

Abstract

BACKGROUND: Transesophageal echocardiogram-guided minimally invasive periventricular device closure of perimembranous ventricular septal defects (pmVSDs) without cardiopulmonary bypass is a treatment option for pmVSDs. We introduce our improvements to this technique and mid-term follow-up results.
METHODS: From May 2011 to May 2014, 187 patients with pmVSDs aged 6 months to 31 years (8.2 ± 10.2 years) were enrolled in this study. The procedure was performed through a new transthoracic approach of 1 to 2 cm without sternotomy. Device selection and the operative procedure were monitored by transesophageal echocardiogram. The patients underwent follow-up examinations of echocardiography and electrocardiogram at 1 month, 3 months, 6 months, and 1 year after the operation and annually thereafter.
RESULTS: The defects were closed successfully in 179 patients (95.7%), and in 8 patients the operation was converted to conventional surgical repair. Six patients (3.4%) had an incomplete right bundle branch block. One patient experienced an intermittent complete atrioventricular block on the fourth day after the operation, and sinus rhythm was restored by corticosteroid therapy after 5 days. A trivial residual shunt was observed in 8 patients (4.5%) during the procedure. The average hospital stay was 3.1 ± 0.9 days. Follow-up in all patients ranged from 1 month to 36 months (median, 12.6 months), and aortic regurgitation, malignant arrhythmia, and device dislocation were not observed in any patients. However, 3 patients (1.7%) still had a trivial residual shunt at their last follow-up.
CONCLUSIONS: Periventricular device closure through a modified transthoracic approach without sternotomy is a potentially safe and effective treatment option for pmVSDs. Controlled studies with long-term follow-up are necessary.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26234660     DOI: 10.1016/j.athoracsur.2015.05.036

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Transcatheter perimembranous ventricular septal defect closure under transthoracic echocardiographic guidance without fluoroscopy.

Authors:  Shouzheng Wang; Wenbin Ouyang; Yao Liu; Fengwen Zhang; Gaili Guo; Guangzhi Zhao; Xiangbin Pan
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Minimally-invasive-perventricular-device-occlusion versus surgical-closure for treating perimembranous-ventricular-septal-defect: 3-year outcomes of a multicenter randomized clinical trial.

Authors:  Wenxin Lu; Fengwen Zhang; Taibing Fan; Tianli Zhao; Yu Han; Xiaopeng Hu; Qi Li; Hao Shi; Xiangbin Pan
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

3.  Effects of transthoracic device closure on ventricular septal defects and reasons for conversion to open-heart surgery: A meta-analysis.

Authors:  Yang Zhou; Ling-Xi Liu; Fei Zhao; Shi-Hai Tang; Hua-Li Peng; Yun-Han Jiang
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

4.  Trans-esophageal echocardiography guided closure of ventricular septal defect with 2 occluders from different incisions simultaneously: A case report.

Authors:  Hui Yang; Jie Mu; Yuyi Zhao; Zizhu Chen; Haibo Song; Jin Liu
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

5.  Personalized Three-Dimensional Printing and Echoguided Procedure Facilitate Single Device Closure for Multiple Atrial Septal Defects.

Authors:  Ping Li; Fang Fang; Xu Qiu; Nan Xu; Yan Wang; Wen-Bin Ouyang; Feng-Wen Zhang; Hai-Bo Hu; Xiang-Bin Pan
Journal:  J Interv Cardiol       Date:  2020-04-25       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.